Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UTL-5g (3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl-) is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. It lowers elevated levels of AST, ALT, creatinine, BUN, and TNF-α, increases the reduced platelet count in mice, and acts as a novel chemo- and radioprotective agent.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 16,500 | |||
5 mg | 在庫あり | ¥ 41,000 | |||
10 mg | 在庫あり | ¥ 64,000 | |||
25 mg | 在庫あり | ¥ 129,500 | |||
50 mg | 在庫あり | ¥ 182,000 | |||
100 mg | 在庫あり | ¥ 259,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 50,000 |
説明 | UTL-5g (3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl-) is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. It lowers elevated levels of AST, ALT, creatinine, BUN, and TNF-α, increases the reduced platelet count in mice, and acts as a novel chemo- and radioprotective agent. |
In vivo | UTL-5g (GBL-5g) lowers levels of TGF-β and TNF-α elevated by lung irradiation[1]. |
別名 | 3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl-, GBL-5g |
分子量 | 271.1 |
分子式 | C11H8Cl2N2O2 |
CAS No. | 646530-37-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (101.44 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UTL-5g 646530-37-2 Apoptosis TNF liver inhibit Inhibitor chemoprotective Tumor Necrosis Factor Receptor radioprotective acute toxicity 3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl- hepatotoxicity anti-inflammatory TNF Receptor UTL 5g UTL5g TNFR GBL-5g inhibitor